Regeneron Pharmaceuticals' Free Cash Flow fell 1328.07% to $922.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.1 billion, marking a year-over-year increase of 1134.91%. This contributed to the annual value of $4.1 billion for FY2025, which is 1134.91% up from last year.
As of Q4 2025, Regeneron Pharmaceuticals' Free Cash Flow stood at $922.0 million, which was down 1328.07% from $1.4 billion recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Free Cash Flow ranged from a high of $3.3 billion in Q3 2021 and a low of $173.5 million during Q2 2024
Over the past 5 years, Regeneron Pharmaceuticals' median Free Cash Flow value was $931.8 million (recorded in 2023), while the average stood at $1.1 billion.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Free Cash Flow skyrocketed by 90500.61% in 2021, and later crashed by 8517.25% in 2022.
Regeneron Pharmaceuticals' Free Cash Flow (Quarter) stood at $2.2 billion in 2021, then decreased by 29.31% to $1.6 billion in 2022, then crashed by 46.53% to $838.3 million in 2023, then increased by 26.83% to $1.1 billion in 2024, then decreased by 13.28% to $922.0 million in 2025.
Its Free Cash Flow stands at $922.0 million for Q4 2025, versus $1.4 billion for Q3 2025 and $925.4 million for Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value